New York, United States
Immunai, founded in 2019, is a United States-based startup that is revolutionizing the Biotechnology and Pharmaceutical industries with its innovative approach. The company's slogan, "Mapping the Immune System with AI to Improve Health," reflects its mission to map and decode the immune system using single-cell biology and artificial intelligence. This approach aims to unleash new therapeutic discoveries, speed up drug development, and enhance patient outcomes.
Immunai's ability to integrate cutting-edge technology positions it as a significant player in the realm of precision medicine. Their most recent major funding event, a $215.00M Series B investment on 01 October 2021, underscores investor confidence in their model. Key investors in this round included 8VC, Alexandria Venture Investments, Koch Disruptive Technologies, Talos, and Piedmont Healthcare. This substantial backing not only provides financial runway but also strategic support as Immunai continues to scale its operations and impact in the healthcare sector.
